Joel Isaacson & Co. LLC Has $94,000 Holdings in Compugen Ltd. (NASDAQ:CGEN)

Joel Isaacson & Co. LLC raised its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 136.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,000 shares of the biotechnology company’s stock after acquiring an additional 30,000 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Compugen were worth $94,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Squarepoint Ops LLC increased its stake in shares of Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 16,253 shares during the last quarter. Rothschild Investment LLC acquired a new stake in Compugen during the second quarter valued at $380,000. ARK Investment Management LLC boosted its position in Compugen by 4.7% during the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after purchasing an additional 48,979 shares during the last quarter. Secure Asset Management LLC acquired a new stake in Compugen during the second quarter valued at $69,000. Finally, Heron Bay Capital Management acquired a new stake in Compugen during the first quarter valued at $32,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Trading Down 1.2 %

CGEN opened at $1.70 on Friday. The stock has a market cap of $151.71 million, a price-to-earnings ratio of -8.95 and a beta of 2.64. Compugen Ltd. has a 1 year low of $0.53 and a 1 year high of $3.03. The stock has a fifty day moving average price of $1.85 and a 200 day moving average price of $1.91.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.06. The company had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.68 million. During the same period in the prior year, the firm earned ($0.11) EPS. As a group, sell-side analysts forecast that Compugen Ltd. will post 0.15 earnings per share for the current fiscal year.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.